



S/N 09/910388

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Lawrence L. Kunz et al.
Serial No.: 09/910388
Filed: July 20, 2001
Title: THERAPEUTIC INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS

Examiner: Unknown
Group Art Unit: 1653
Docket: 295.003US5

TECH CENTER 1600/2900

MAR 12 2003

RECEIVED

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Supplemental Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. § 1.97(b), it is believed that no fee or statement is required with the Supplemental Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Account No. 19-0743 in order to have this Supplemental Information Disclosure Statement considered.

The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
LAWRENCE L. KUNZ ET AL.
By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
612-373-6959

Date March 5, 2003

By Janet H. Embretson
Janet H. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this day of March, 2003

Name


Signature

Substitute for form 1449A/PTO

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/910388
Filing Date	July 20, 2001
First Named Inventor	Kunz, Lawrence
Group Art Unit	1653
Examiner Name	Unknown

Sheet 1 of 2

Attorney Docket No: 295.003US5

RECEIVED
MAR 12 2003
TECH CENTER 1600/2900

US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	Filing Date If Appropriate
	2002/0040064	04/04/2002	Kunz et al.	514	656	07/20/2001
	2002/0086896	07/04/2002	Kunz et al.	514	449	12/18/2001
	2003/0039675	02/27/2003	Kunz et al.	424	423	11/27/2001
	5,175,235	12/29/1992	Domb et al.	528	271	06/04/1990
	5,252,579	10/12/1993	Skotnicki et al.	514	291	02/16/1993
	5,290,271	03/01/1994	Jernberg	604	891.1	07/29/1993
	5,302,584	04/12/1994	Kao et al.	514	80	04/23/1993
	5,362,718	11/08/1994	Skotnicki et al.	514	63	04/18/1994
	5,387,680	02/07/1995	Nelson	540	456	08/10/1993
	5,411,967	05/02/1995	Kao et al.	514	291	04/08/1994
	5,416,205	05/16/1995	della Valle et al.	514	54	11/22/1993
	5,422,362	06/06/1995	Vincent et al.	514	410	07/29/1993
	5,462,966	10/31/1995	Sofia	514	483	10/15/1993
	5,496,581	03/05/1996	Yianni et al.	427	2.12	11/10/1993
	5,504,091	04/02/1996	Molnar-Kimber et al.	514	291	04/14/1994
	5,525,610	06/11/1996	Caufield et al.	514	291	04/26/1995
	5,563,145	10/08/1996	Failli et al.	514	291	12/07/1994
	5,677,295	10/14/1997	Failli et al.	514	183	05/30/1996
	5,981,568	11/09/1999	Kunz et al.	514	411	03/31/1997
	6,171,609	01/09/2001	Kunz	424	422	10/23/1995
	6,306,421	10/23/2001	Kunz et al.	424	423	03/31/1997
	6,358,989	03/19/2002	Kunz et al.	514	411	07/26/1999
	6,491,938	12/10/2002	Kunz et al.	424	423	06/29/2001
	6,515,009	02/04/2003	Kunz et al.	514	411	02/15/1995

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Class	Subclass	T ²
	CA 2,086,642	07/10/1993	Morris et al.	A61K	31/71	
	EP 0 551 182	07/14/1993	Morris et al.	A61K	31/70	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)



Complete if Known

Application Number	09/910388
Filing Date	July 20, 2001
First Named Inventor	Kunz, Lawrence
Group Art Unit	1653
Examiner Name	Unknown

Sheet 2 of 2

Attorney Docket No: 295.003US5

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		AKSELBAND et al., "Rapamycin Inhibits Spontaneous and Fibroblast Growth Factor Beta-Stimulated Proliferation of Endothelial Cells and Fibroblasts", <u>Transplantation Proceedings</u> , 23, 2833-2836 (1991).	
		GRAHAM et al., "Dexamethasone Inhibits Growth and Na:H Exchange in Vascular Smooth Muscle Cells", <u>Journal of Endocrinology</u> , 129 (Suppl.), Abstract 180, 10th Joint Meeting of British Endocrine Societies, Brighton, England, UK, April 15-18, 1991.	
		GREGORY et al., "Rapamycin Inhibits Arterial Intimal Thickening Caused by Both Alloimmune and Mechanical Injury", <u>Transplantation</u> , 55, 1409-1418 (1993)	
		MEISER et al., "Effects of Cyclosporin, FK506, and Rapamycin on Graft-Vessel Disease", <u>The Lancet</u> , 338, 1297-1298 (1991).	
		MORRIS et al., "Immunosuppressive Effects of the Morpholinoethyl Ester of Mycophenolic Acid (RS-61443) in Rat and Nonhuman Primate Recipients of Heart Allografts", <u>Transplantation Proceedings</u> , 23, 19-25 (1991).	
		MORRIS, "Rapamycins: Antifungal, Antitumor, Antiproliferative, and Immunosuppressive Macrolides", <u>Transplantation Reviews</u> , 6, 39-87 (1992).	
		NAKANO, "Glucocorticoid Inhibits Thrombin-Induced Expression of Platelet-Derived Growth Factor A-chain and Heparin-Binding Epidermal Growth Factor-Like Growth Factor in Human Aortic Smooth Muscle Cells", <u>The Journal of Biological Chemistry</u> , 268, 22941-22947 (1993).	

RECEIVED

MAR 12 2003

TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached